TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Tango Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$23.53+1.49 (+6.76%)
Close on Oct 19, 2026
- Market cap
- $3.53B
- P/E (TTM)
- –
- Dividend yield
- –
Tango Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q4 22 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue [Member] | $0 | $53.81M | $3.18M | $5.39M | $4.12M | $11.61M | $7.78M | $6.47M | $5.43M | $10.73M | $9.60M | $6.41M | – | -100.0% |
| License Revenue [Member] | – | – | – | – | $0 | $0 | $12.10M | – | $0 | $0 | $5.00M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Tango Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.